ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / February 22, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will present at or attend several upcoming virtual healthcare investor events in February and March 2021.
Conference Presentation Details:
- Event: Leerink 10th Annual Global Healthcare Conference
- Date/Time: Thursday, February 25, 8:40 AM - 9:10 AM ET (2:40 PM - 3:10 PM CET)
- Event: Cowen 41st Annual Health Care Conference
- Date/Time: Tuesday, March 2, 2021, 10:30 AM - 11:00 AM ET (4:30 PM - 5:00 PM CET)
- Event: H.C. Wainwright Global Life Sciences Conference
- Date/Time: Tuesday, March 9, 2021 7:00 AM - 7:30 AM ET (1:00 PM - 1:30 PM CET)
Conference Participation Details:
- Event: Credit Suisse Global Virtual Healthcare Conference
- Date: March 2-4, 2021
All webcasted presentations will be made available on the Molecular Partners website.
About Molecular Partners AG
Molecular Partners AG is a clinical-stage biotech company developing DARPin® therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin® therapeutics in the areas of ophthalmology, oncology, and infectious disease and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
For further details, please contact:
Tel: +1 781 420 2361
Shai Biran, Ph.D.
Tel: +1 978 254 6286
Tel: +1 617 461 2442
Thomas Schneckenburger, IR & European Media
Tel: +41 79 407 9952
This press release may contain certain forward-looking statements relating to the company and its business. Although the company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the company's control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as "target," "believe," "expect," "aim," "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could," and other words and terms of similar meaning or the negative thereof. Forward-looking statements involve certain risks, uncertainties, and other factors which could cause the actual results, financial condition, performance, or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. Except as required by law, the company assumes no obligation to update any such forward-looking statements or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new.
SOURCE: Molecular Partners AG